Maxigen Biotech (TPE:1783) Cash-to-Debt : 9,692.76 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Maxigen Biotech's cash to debt ratio for the quarter that ended in Mar. 2024 was 9,692.76.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Maxigen Biotech could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Maxigen Biotech's Cash-to-Debt or its related term are showing as below:

TPE:1783' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.5 Med: 22.29 Max: 129322
Current: 9692.76

During the past 13 years, Maxigen Biotech's highest Cash to Debt Ratio was 129322.00. The lowest was 4.50. And the median was 22.29.

TPE:1783's Cash-to-Debt is ranked better than
94.56% of 864 companies
in the Medical Devices & Instruments industry
Industry Median: 1.875 vs TPE:1783: 9692.76

Maxigen Biotech Cash-to-Debt Historical Data

The historical data trend for Maxigen Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Maxigen Biotech Cash-to-Debt Chart

Maxigen Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

29.45

18.37

55.46

No Debt

8,651.64

Maxigen Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	8,428.50	8,651.64	9,692.76

Competitive Comparison of Maxigen Biotech's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maxigen Biotech's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cash-to-Debt falls into.

Maxigen Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Maxigen Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	432.582	/	(0.05	+	0)
	=	8,651.64

Maxigen Biotech's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	484.638	/	(0.05	+	0)
	=	9,692.76

Maxigen Biotech (TPE:1783) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Maxigen Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxigen Biotech (TPE:1783) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333

Website

https://www.mbi.com.tw

Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines